JP2022535986A5 - - Google Patents

Info

Publication number
JP2022535986A5
JP2022535986A5 JP2021573749A JP2021573749A JP2022535986A5 JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5 JP 2021573749 A JP2021573749 A JP 2021573749A JP 2021573749 A JP2021573749 A JP 2021573749A JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5
Authority
JP
Japan
Prior art keywords
compound
general formula
alkyl
halo
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535986A (ja
JP7862174B2 (ja
Filing date
Publication date
Priority claimed from GBGB1908453.2A external-priority patent/GB201908453D0/en
Application filed filed Critical
Publication of JP2022535986A publication Critical patent/JP2022535986A/ja
Publication of JP2022535986A5 publication Critical patent/JP2022535986A5/ja
Application granted granted Critical
Publication of JP7862174B2 publication Critical patent/JP7862174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573749A 2019-06-12 2020-06-12 呼吸器の疾患を処置するためのtmem16aのモジュレータ Active JP7862174B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908453.2A GB201908453D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease
GB1908453.2 2019-06-12
PCT/GB2020/051414 WO2020249956A1 (en) 2019-06-12 2020-06-12 Modulators of tmem16a for treating respiratory disease

Publications (3)

Publication Number Publication Date
JP2022535986A JP2022535986A (ja) 2022-08-10
JP2022535986A5 true JP2022535986A5 (cg-RX-API-DMAC7.html) 2023-06-13
JP7862174B2 JP7862174B2 (ja) 2026-05-19

Family

ID=67386340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573749A Active JP7862174B2 (ja) 2019-06-12 2020-06-12 呼吸器の疾患を処置するためのtmem16aのモジュレータ

Country Status (6)

Country Link
US (1) US12415793B2 (cg-RX-API-DMAC7.html)
EP (1) EP3983069A1 (cg-RX-API-DMAC7.html)
JP (1) JP7862174B2 (cg-RX-API-DMAC7.html)
CN (1) CN114269433B (cg-RX-API-DMAC7.html)
GB (1) GB201908453D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020249956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
BR112022021391A2 (pt) * 2020-06-30 2023-01-10 Bayer Ag N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
GB9515975D0 (en) * 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
EP1032265B1 (en) * 1997-11-20 2003-10-29 Cerus Corporation New psoralens for pathogen inactivation
JP2004518723A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ピリミジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DE10138578A1 (de) * 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
DE10251019A1 (de) * 2002-11-02 2004-05-19 Aventis Pharma Deutschland Gmbh Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
DE10300017A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Selektive MMP 13 Inhibitoren
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
US20110269834A1 (en) * 2008-08-21 2011-11-03 The Board Of Trustees Of The University Of Illinois Compounds and methods for treating respiratory diseases
FR2958849A1 (fr) * 2010-04-14 2011-10-21 Boiron Medicament homeopathique a activite anti-cancereuse
CN107441097A (zh) * 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9505743B2 (en) * 2012-10-15 2016-11-29 Aquilus Pharmaceuticals, Inc. Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
ES2885823T3 (es) * 2013-06-03 2021-12-15 Univ Bar Ilan Liposomas para modulación de proteína de síndrome de Wiskott-Aldrich
EP3020710A4 (en) * 2013-07-11 2016-12-14 Consejo Superior De Investig Científicas (Csic) OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
SG11201803242TA (en) * 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
JP7116745B2 (ja) * 2017-04-28 2022-08-10 レセプトス・リミテッド・ライアビリティ・カンパニー 新規なglp-1受容体モジュレーター
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
WO2019079609A1 (en) * 2017-10-20 2019-04-25 The Regents Of The University Of California SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Similar Documents

Publication Publication Date Title
RU2763936C1 (ru) Производные 1,3,4-оксадиазола, как ингибитор гистондезацетилазы 6 и содержащая их фармацевтическая композиция
JP5578083B2 (ja) 2h−クロメン化合物及びその誘導体
JPS63258416A (ja) カルバゾリル−(4)−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び/又はβ−受容体閉塞作用を有する薬剤
RU2203897C2 (ru) Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство
KR101666729B1 (ko) Mgat2 억제제로서의 아릴 디히드로피리디논 및 피페리디논
US20040019113A1 (en) Phosphate transport inhibitors
EP1308438B1 (en) 3-substituted urea derivatives and medicinal use thereof
HUE026249T2 (en) Acrylamide derivatives may be used as inhibitors of mitochondrial permeability transition
JP2021512143A5 (cg-RX-API-DMAC7.html)
JP2007509852A5 (cg-RX-API-DMAC7.html)
WO2001025190A1 (en) Novel diarylamide derivatives and use thereof as medicines
JP2001509166A (ja) 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド
KR20120092655A (ko) Cns 장애 치료용 옥사졸린 유도체
KR20070057965A (ko) 염증 및 면역 관련 용도를 위한 화합물
JP2756975B2 (ja) ピリジニウム誘導体
KR20060066711A (ko) 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법
JP2008502614A5 (cg-RX-API-DMAC7.html)
JP2006528617A (ja) 5−ht2b受容体アンタゴニスト
JPWO2005026127A1 (ja) プラスミノゲンアクチベータインヒビター−1阻害剤
JP2008516902A5 (cg-RX-API-DMAC7.html)
CN101420950B (zh) 杜兴肌营养不良的治疗
JP2002503247A (ja) Pge2アゴニストおよびアンタゴニストとして有用なオキサゾール化合物
CN102030700A (zh) 苯甲酰胺基羧酸类化合物及其制法和药物用途
MX2011007048A (es) Toluidin sulfonamidas y su uso.
JP5161873B2 (ja) (2r)−2−[(4−スルホニル)アミノフェニル]プロパンアミド類と、それらを含有する医薬組成物